Prasit P - Search Results

1

Rational design of potent and selective NH-linked aryl/heteroaryl cathepsin K inhibitors.

Robichaud J, Bayly C, Oballa R, Prasit P, Mellon C, Falgueyret JP, Percival MD, Wesolowski G, Rodan SB. Robichaud J, et al. Among authors: prasit p. Bioorg Med Chem Lett. 2004 Aug 16;14(16):4291-5. doi: 10.1016/j.bmcl.2004.05.087. Bioorg Med Chem Lett. 2004. PMID: 15261289

2

A novel class of nonpeptidic biaryl inhibitors of human cathepsin K.

Robichaud J, Oballa R, Prasit P, Falgueyret JP, Percival MD, Wesolowski G, Rodan SB, Kimmel D, Johnson C, Bryant C, Venkatraman S, Setti E, Mendonca R, Palmer JT. Robichaud J, et al. Among authors: prasit p. J Med Chem. 2003 Aug 14;46(17):3709-27. doi: 10.1021/jm0301078. J Med Chem. 2003. PMID: 12904076

3

Design and synthesis of tri-ring P3 benzamide-containing aminonitriles as potent, selective, orally effective inhibitors of cathepsin K.

Palmer JT, Bryant C, Wang DX, Davis DE, Setti EL, Rydzewski RM, Venkatraman S, Tian ZQ, Burrill LC, Mendonca RV, Springman E, McCarter J, Chung T, Cheung H, Janc JW, McGrath M, Somoza JR, Enriquez P, Yu ZW, Strickley RM, Liu L, Venuti MC, Percival MD, Falgueyret JP, Prasit P, Oballa R, Riendeau D, Young RN, Wesolowski G, Rodan SB, Johnson C, Kimmel DB, Rodan G. Palmer JT, et al. Among authors: prasit p. J Med Chem. 2005 Dec 1;48(24):7520-34. doi: 10.1021/jm058198r. J Med Chem. 2005. PMID: 16302794

4

Practical asymmetric synthesis of a potent Cathepsin K inhibitor. Efficient palladium removal following Suzuki coupling.

Chen CY, Dagneau P, Grabowski EJ, Oballa R, O'Shea P, Prasit P, Robichaud J, Tillyer R, Wang X. Chen CY, et al. Among authors: prasit p. J Org Chem. 2003 Apr 4;68(7):2633-8. doi: 10.1021/jo0205614. J Org Chem. 2003. PMID: 12662032

5

Allosteric inhibitors of Akt1 and Akt2: discovery of [1,2,4]triazolo[3,4-f][1,6]naphthyridines with potent and balanced activity.

Li Y, Liang J, Siu T, Hu E, Rossi MA, Barnett SF, Defeo-Jones D, Jones RE, Robinson RG, Leander K, Huber HE, Mittal S, Cosford N, Prasit P. Li Y, et al. Among authors: prasit p. Bioorg Med Chem Lett. 2009 Feb 1;19(3):834-6. doi: 10.1016/j.bmcl.2008.12.017. Epub 2008 Dec 7. Bioorg Med Chem Lett. 2009. PMID: 19097777

6

Identification of the first potent, selective and bioavailable PPARα antagonist.

Bravo Y, Baccei CS, Broadhead A, Bundey R, Chen A, Clark R, Correa L, Jacintho JD, Lorrain DS, Messmer D, Stebbins K, Prasit P, Stock N. Bravo Y, et al. Among authors: prasit p. Bioorg Med Chem Lett. 2014 May 15;24(10):2267-72. doi: 10.1016/j.bmcl.2014.03.090. Epub 2014 Apr 4. Bioorg Med Chem Lett. 2014. PMID: 24745969

7

Water soluble prodrug of a COX-2 selective inhibitor suitable for intravenous administration in models of cerebral ischemia.

Smith ND, Reger TS, Payne J, Zunic J, Lorrain D, Correa L, Stock N, Cramer M, Chen W, Yang J, Prasit P, Munoz B. Smith ND, et al. Among authors: prasit p. Bioorg Med Chem Lett. 2005 Jul 1;15(13):3197-200. doi: 10.1016/j.bmcl.2005.05.002. Bioorg Med Chem Lett. 2005. PMID: 15936193

8

Sodium [2'-[(cyclopropanecarbonyl-ethyl-amino)-methyl]-4'-(6-ethoxy-pyridin-3-yl)-6-methoxy-biphenyl-3-yl]-acetate (AM432): a potent, selective prostaglandin D2 receptor antagonist.

Stock N, Volkots D, Stebbins K, Broadhead A, Stearns B, Roppe J, Parr T, Baccei C, Bain G, Chapman C, Correa L, Darlington J, King C, Lee C, Lorrain DS, Prodanovich P, Santini A, Evans JF, Hutchinson JH, Prasit P. Stock N, et al. Among authors: prasit p. Bioorg Med Chem Lett. 2011 Feb 1;21(3):1036-40. doi: 10.1016/j.bmcl.2010.12.016. Epub 2010 Dec 9. Bioorg Med Chem Lett. 2011. PMID: 21211969

9

The geminal dimethyl analogue of Flurbiprofen as a novel Abeta42 inhibitor and potential Alzheimer's disease modifying agent.

Stock N, Munoz B, Wrigley JD, Shearman MS, Beher D, Peachey J, Williamson TL, Bain G, Chen W, Jiang X, St-Jacques R, Prasit P. Stock N, et al. Among authors: prasit p. Bioorg Med Chem Lett. 2006 Apr 15;16(8):2219-23. doi: 10.1016/j.bmcl.2006.01.033. Epub 2006 Feb 7. Bioorg Med Chem Lett. 2006. PMID: 16455248

10

5-Lipoxygenase-activating protein inhibitors. Part 2: 3-{5-((S)-1-Acetyl-2,3-dihydro-1H-indol-2-ylmethoxy)-3-tert-butylsulfanyl-1-[4-(5-methoxy-pyrimidin-2-yl)-benzyl]-1H-indol-2-yl}-2,2-dimethyl-propionic acid (AM679)--a potent FLAP inhibitor.

Stock N, Baccei C, Bain G, Broadhead A, Chapman C, Darlington J, King C, Lee C, Li Y, Lorrain DS, Prodanovich P, Rong H, Santini A, Zunic J, Evans JF, Hutchinson JH, Prasit P. Stock N, et al. Among authors: prasit p. Bioorg Med Chem Lett. 2010 Jan 1;20(1):213-7. doi: 10.1016/j.bmcl.2009.10.131. Epub 2009 Oct 31. Bioorg Med Chem Lett. 2010. PMID: 19914828

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

56 results

Search Page

Filters